<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of acute and chronic pouchitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of acute and chronic pouchitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of acute and chronic pouchitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bo Shen, MD, AGAF, FACG, FASGE</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sunanda V Kane, MD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3136327948"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is performed for treating patients with ulcerative colitis (UC) or familial adenomatous polyposis (FAP). However, patients with IPAA are at risk for pouchitis, an inflammatory disorder that typically presents with increased stool frequency and urgency and is a common complication of IPAA or a continent ileostomy (eg, Kock pouch). </p><p>The focus of this topic is management of acute pouchitis and chronic pouchitis. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of pouchitis are discussed in detail, separately. (See  <a class="medical medical_review" href="/d/html/4073.html" rel="external">"Pouchitis: Epidemiology, pathogenesis, clinical features, and diagnosis"</a>.)</p><p>Surgical management of UC is discussed separately. (See  <a class="medical medical_review" href="/d/html/1375.html" rel="external">"Surgical management of ulcerative colitis"</a>.)</p><p>Management of FAP is discussed separately. (See  <a class="medical medical_review" href="/d/html/2592.html" rel="external">"Familial adenomatous polyposis: Screening and management of patients and families"</a>.)</p><p>Surgical complications and outcomes associated with proctocolectomy and IPAA are discussed separately. (See  <a class="medical medical_review" href="/d/html/15017.html" rel="external">"Restorative proctocolectomy with ileal pouch-anal anastomosis: Laparoscopic approach"</a>.)</p><p class="headingAnchor" id="H2381205477"><span class="h1">SPECTRUM OF DISEASE</span><span class="headingEndMark"> — </span>Pouchitis and other ileal pouch disorders (eg, cuffitis) have been classified based on disease characteristics (eg, duration of symptoms, response to antibiotics, pattern of activity, etiology). Classification of pouch disorders is supported by consensus guidelines from the International Ileal Pouch Consortium and is discussed in more detail separately [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/4073.html" rel="external">"Pouchitis: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Spectrum of disease'</a>.)</p><p>Many patients with ileal pouches have some degree of endoscopic inflammation of the ileal pouch reservoir, and pouchitis likely represents a disease spectrum with a range of presentations that may evolve over time. As an example, acute antibiotic-responsive pouchitis may evolve into chronic antibiotic-refractory pouchitis. </p><p class="headingAnchor" id="H2414575803"><span class="h1">TREATMENT GOALS</span><span class="headingEndMark"> — </span>The goal of therapy is to alleviate symptoms and achieve clinical and endoscopic remission by demonstrating mucosal healing. Histologic improvement (ie, resolution of acute inflammatory cell infiltrate) is emerging as an additional component of disease remission [<a href="#rid2">2,3</a>]. </p><p>Assessing treatment response for patients with pouchitis includes recognizing that the normal stool pattern for patients with an ileal pouch is four to seven formed stools daily without seepage, and typically without nocturnal bowel movements. </p><p>Endoscopic healing is an important goal of therapy because symptoms alone may not reflect the inflammatory status of the pouch [<a href="#rid2">2,4-6</a>]. However, the definition of mucosal healing varies among clinical studies. For example, endoscopic mucosal healing has been defined as completely normal mucosa [<a href="#rid7">7</a>], the absence of erosions or ulcers [<a href="#rid8">8</a>], or Pouchitis Disease Activity Index (PDAI) endoscopy subscores of 0 or 1 as well as no ulcers [<a href="#rid9">9</a>]. The PDAI and other scoring systems are described separately. (See  <a class="medical medical_review" href="/d/html/4073.html" rel="external">"Pouchitis: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Scoring systems for assessing disease activity'</a>.)</p><p class="headingAnchor" id="H3136327966"><span class="h1">PRIMARY PREVENTION</span><span class="headingEndMark"> — </span>For primary prevention of pouchitis and to promote optimal pouch function, patients with an ileal pouch are advised to:</p><p class="bulletIndent1"><span class="glyph">●</span>Avoid nonsteroidal antiinflammatory drugs (NSAIDs) because NSAIDs are associated with an increased risk for chronic pouchitis [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maintain ideal body weight, because weight gain is a risk factor for pouch failure, and this is discussed separately. (See  <a class="medical medical_review" href="/d/html/15017.html" rel="external">"Restorative proctocolectomy with ileal pouch-anal anastomosis: Laparoscopic approach", section on 'Risk factors for pouch failure'</a>.)</p><p></p><p>We do not routinely use probiotics or other pharmacologic agents for primary prevention of acute pouchitis. Studies on probiotics for primary prevention of acute pouchitis after pouch construction are uncertain and are limited by small trials [<a href="#rid11">11</a>]. Probiotics are organisms belonging to the gut flora that may have health benefits. (See  <a class="medical medical_review" href="/d/html/2603.html" rel="external">"Probiotics for gastrointestinal diseases"</a>.)</p><p>However, probiotics are used for secondary prevention of active pouchitis. (See <a class="local">'Maintenance therapy'</a> below.) </p><p class="headingAnchor" id="H3136328003"><span class="h1">ACUTE IDIOPATHIC POUCHITIS</span></p><p class="headingAnchor" id="H2975551437"><span class="h2">General measures</span><span class="headingEndMark"> — </span>Accurate and timely diagnosis and classification of pouchitis are key for successful treatment. Patients with acute idiopathic pouchitis have endoscopic evidence of active pouch inflammation without a clear cause based on histology, stool studies, and blood tests, and the following measures apply to such patients  (<a class="graphic graphic_algorithm graphicRef129598" href="/d/graphic/129598.html" rel="external">algorithm 1</a>) (see  <a class="medical medical_review" href="/d/html/4073.html" rel="external">"Pouchitis: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Evaluation'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Avoid nonsteroidal antiinflammatory drugs (NSAIDs) – We advise patients with pouchitis to avoid NSAIDs because NSAIDs are associated with increased risk for chronic pouchitis [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dietary adjustments – The author advises patients with normal pouches or active pouchitis to adhere to a diet that is low in poorly digested carbohydrates and low in fiber, as fermentation of dietary carbohydrates or fiber by small intestinal bacterial overgrowth in the pouch can cause increased stool frequency and bloating. Of note, dietary modification is used for symptomatic relief, rather than healing of pouch inflammation. The dietary approach is similar to the low fermentable oligo-, di-, monosaccharides and polyols diet. (See  <a class="medical medical_review" href="/d/html/2631.html" rel="external">"Treatment of irritable bowel syndrome in adults", section on 'Dietary modification'</a>.) </p><p></p><p class="bulletIndent1">Preliminary data suggest that a Crohn Disease Exclusion Diet was associated with improvement in symptoms and endoscopic healing [<a href="#rid12">12</a>]. In addition, fruit consumption may be associated with a lower risk of pouchitis [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Specialty consultation – We suggest that patients with pouchitis are referred to an inflammatory bowel disease center or pouch clinic for long-term management.</p><p></p><p>For patients who progress to antibiotic-dependent pouchitis or chronic antibiotic-refractory pouchitis (CARP), management includes medical therapy and modification of risk factors [<a href="#rid14">14</a>]. (See <a class="local">'Managing nonresponders'</a> below and <a class="local">'Managing relapse'</a> below.)</p><p class="headingAnchor" id="H3136328015"><span class="h2">Initial therapy</span><span class="headingEndMark"> — </span>First-line therapy for acute pouchitis consists of an oral antibiotic for two weeks (<a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> 500 mg every 12 hours). Alternatives to ciprofloxacin for initial therapy include <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> 500 mg every 12 hours or <a class="drug drug_general" data-topicid="10205" href="/d/drug information/10205.html" rel="external">tinidazole</a> 500 mg every 12 hours. </p><p>Selecting initial therapy for acute idiopathic pouchitis has been guided by clinical experience and few small trials [<a href="#rid11">11,15,16</a>]. In a systematic review that included one trial of 16 patients with acute pouchitis, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> resulted in higher rates of remission after two weeks compared with <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> (100 versus 33 percent, risk ratio 2.68 [95% CI 1.13 to 6.35]) [<a href="#rid11">11,15</a>]. In addition, patients treated with ciprofloxacin had lower rates of adverse events (eg, vomiting, dysgeusia, peripheral neuropathy) (0 versus 33 percent). We consider <a class="drug drug_general" data-topicid="10205" href="/d/drug information/10205.html" rel="external">tinidazole</a> to be a reasonable alternative to ciprofloxacin based on the author's experience and limited indirect data [<a href="#rid16">16</a>]. </p><p>The use of antibiotic therapy has been supported by studies that have linked intestinal microbiota to the development of pouchitis. (See  <a class="medical medical_review" href="/d/html/4073.html" rel="external">"Pouchitis: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Intestinal microbiota'</a>.)</p><p>Most patients with acute pouchitis have symptomatic improvement (eg, improved stool frequency, no urgency) within three days after initiating antibiotic therapy [<a href="#rid15">15,17</a>]. </p><p>Patients who respond to initial treatment but have frequent relapses (≥3 episodes per year) are described as having antibiotic-dependent chronic pouchitis. For such patients, we suggest maintenance therapy with a probiotic or a nonabsorbable antibiotic. (See <a class="local">'Managing relapse'</a> below.) </p><p>However, we do not routinely use probiotics for patients with uncomplicated acute pouchitis, and this approach is supported by consensus guidelines [<a href="#rid14">14</a>]. </p><p class="headingAnchor" id="H3136328021"><span class="h2">Subsequent management</span><span class="headingEndMark"> — </span>For patients with acute pouchitis who do not respond to initial antibiotic treatment, we perform stool culture and susceptibility testing of bacterial flora and select a single active antibiotic based on those results for a four-week course [<a href="#rid18">18,19</a>]. If such testing is not available, we give a prolonged course (eg, four weeks) of dual oral antibiotic therapy consisting of <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (500 mg every 12 hours) combined with <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> (500 mg every 12 hours) or <a class="drug drug_general" data-topicid="10205" href="/d/drug information/10205.html" rel="external">tinidazole</a> (500 mg every 12 hours) or <a class="drug drug_general" data-topicid="10202" href="/d/drug information/10202.html" rel="external">rifaximin</a> (550 mg every 12 hours) [<a href="#rid14">14</a>].</p><p>For patients who respond to ≥4 weeks of antibiotic therapy (based on susceptibility testing of bacterial flora or empiric treatment), we give maintenance therapy to prevent relapse, similar to the approach for patients with antibiotic-dependent chronic pouchitis. (See <a class="local">'Managing relapse'</a> below.)</p><p>For patients with persistent symptoms despite ≥4 weeks of antibiotic therapy, we reassess the patient before proceeding with additional treatment options. (See <a class="local">'Managing nonresponders'</a> below.)</p><p>Dual antibiotic therapy has been associated with symptomatic and endoscopic improvement in patients with pouchitis. In four observational studies including a total of 86 patients with active pouchitis, dual antibiotic therapy (<a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> plus <a class="drug drug_general" data-topicid="10205" href="/d/drug information/10205.html" rel="external">tinidazole</a> or <a class="drug drug_general" data-topicid="10202" href="/d/drug information/10202.html" rel="external">rifaximin</a> or <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>) was associated with clinical response or remission in 73 patients (85 percent) [<a href="#rid18">18,20-22</a>].</p><p>For patients with long-term antibiotic use, the reported rates of infection or colonization with antibiotic-resistant bacterial strains are low [<a href="#rid23">23-25</a>]. However, the risk of long-term use of absorbable antibiotics remains a concern. Long-term antimicrobial therapy for antibiotic-responsive pouchitis may result in colonization of ciprofloxacin-resistant nonpathogenetic intestinal microbiota [<a href="#rid24">24</a>]. As an example, in one study that examined stool samples from 43 patients with an ileal pouch, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> use was associated with increased risk of having bacteria with quinolone-resistant mutations in the <em>gyrA</em> and <em>parC </em>genes [<a href="#rid25">25</a>].  </p><p class="headingAnchor" id="H100698052"><span class="h2">Assessing response</span><span class="headingEndMark"> — </span>For patients with acute idiopathic pouchitis, response to antibiotic therapy is typically assessed clinically (symptomatic improvement) and endoscopically (pouchoscopy with biopsy) after completing therapy, and this approach is supported by consensus guidelines [<a href="#rid14">14</a>]. While endoscopic mucosal healing may lag behind symptomatic improvement, mucosal healing is a treatment target for patients with pouchitis [<a href="#rid7">7</a>].  </p><p>Correlation between symptom, endoscopic, and histologic scores is limited in studies on treatment outcomes for patients with pouchitis [<a href="#rid4">4,26</a>]. Ideally, a combined score consisting of symptoms, endoscopy, and histology should be used to measure treatment response [<a href="#rid14">14</a>]. Some studies have used disease activity instruments to measure response to treatment. As an example, in a study using a modified RAND/University of California Los Angeles appropriateness process, items that appropriately evaluated pouchitis included stool frequency and fecal urgency; severity of endoscopic findings (ie, extent of pouch body inflammation and ulceration); and histologic findings (ie, lamina propria chronic inflammation, epithelial and lamina propria neutrophils, epithelial damage, erosions and ulcers) [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H3837473550"><span class="h1">MANAGING RELAPSE</span></p><p class="headingAnchor" id="H1184019089"><span class="h2">Patients with infrequent relapse</span><span class="headingEndMark"> — </span>For patients with acute pouchitis who have a clinical relapse of pouchitis after achieving remission with &lt;4 weeks of antibiotic therapy, we begin another course of antibiotic monotherapy for two weeks. When treating relapse, the single antibiotic agent that was effective initially may be used again. (See <a class="local">'Initial therapy'</a> above.)  </p><p>For patients who have infrequent relapses (ie, &lt;3 episodes of acute pouchitis per year), we do not use maintenance therapy.</p><p class="headingAnchor" id="H457382675"><span class="h2">Patients with frequent relapse</span><span class="headingEndMark"> — </span>Patients with acute pouchitis who respond initially to antibiotic therapy (ie, &lt;4 weeks) but who relapse ≥3 times per year are given long-term maintenance therapy, typically with a probiotic or an alternative agent [<a href="#rid14">14</a>]. (See <a class="local">'Maintenance therapy'</a> below.)</p><p>Patients who develop symptoms of active pouchitis while on maintenance therapy are reassessed before proceeding with additional treatment options. (See <a class="local">'Managing nonresponders'</a> below.)</p><p class="headingAnchor" id="H1941944896"><span class="h2">Maintenance therapy</span><span class="headingEndMark"> — </span>For patients with pouchitis who respond initially to antibiotic therapy but who relapse ≥3 times per year or who required ≥4 weeks of antibiotic therapy (dual or monotherapy) initially (ie, chronic antibiotic-dependent pouchitis), we typically use maintenance therapy with a probiotic. Initial maintenance therapy consists of the probiotic VSL#3 (<em>Bifidobacterium breve, B. longum, B. infantis, </em><a class="drug drug_general" data-topicid="9541" href="/d/drug information/9541.html" rel="external">Lactobacillus</a> acidophilus, L. plantarum, L. paracasei, L. bulgaricus, Streptococcus thermophilus, 6 to 9 g daily) with the rationale that changes in the microflora have been demonstrated in patients with pouchitis [<a href="#rid28">28,29</a>]. [Note: Studies before 2015 were performed with the original Italian (DeSimone) preparation. In the United States, VSL#3 formulation is somewhat different and has different functional properties [<a href="#rid30">30,31</a>]. General issues of regulation and safety of dietary supplements are discussed separately. (See  <a class="medical medical_review" href="/d/html/1392.html" rel="external">"Overview of herbal medicine and dietary supplements"</a>.)]</p><p>Data supporting the use of VSL#3 for maintaining remission are mixed [<a href="#rid32">32-35</a>]. In a trial including 40 patients with chronic pouchitis, maintenance therapy with VSL#3 (6 g daily) resulted in lower relapse rates after nine months compared with placebo (15 versus 100 percent) [<a href="#rid32">32</a>]. However, in open-label studies, the response rate to VSL#3 was lower than that reported in randomized trials and the discontinuation rate was high [<a href="#rid33">33,35</a>]. In a study of 31 patients with antibiotic-dependent pouchitis who received VSL#3 as maintenance therapy, 25 patients (81 percent) discontinued the probiotic at eight months due to lack of efficacy or the development of adverse effects [<a href="#rid33">33</a>]. It is unclear if these conflicting results are due to differences in study population characteristics, inclusion criteria, induction therapy with antibiotics, and/or the composition and dosage of the probiotic agents.</p><p>An alternative to chronic probiotic therapy for maintenance is a nonabsorbable antibiotic or low-dose systemic antibiotic; however, risk of adverse effects, antibiotic resistance, and cost are limitations of this strategy. We do not routinely use antibiotic therapy for long-term maintenance therapy (ie, &gt;3 months). Options for maintenance therapy include <a class="drug drug_general" data-topicid="10202" href="/d/drug information/10202.html" rel="external">rifaximin</a> (in doses ranging from 200 mg once daily to 600 mg every eight hours) and low-dose <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (250 to 500 mg daily) [<a href="#rid33">33</a>]. Rifaximin, a nonabsorbable antibiotic, has the advantage of a favorable safety profile; however, its long-term use may be limited by cost. Adverse effects of ciprofloxacin and other fluoroquinolones (eg, risk of tendinopathy, <em>Clostridioides difficile </em>infection, aortic dissection) are discussed separately. (See  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Adverse effects'</a>.) </p><p>Data on efficacy of antibiotic maintenance therapy for chronic pouchitis are limited to small observational studies [<a href="#rid33">33,36,37</a>]. As an example, in a case series including 39 patients with chronic antibiotic-dependent pouchitis who had been maintained on antibiotics for at least one year, symptomatic remission was achieved by eight patients (21 percent) over a mean duration of six years [<a href="#rid37">37</a>]. Adverse effects from long-term antibiotic use (ie, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>) developed in 11 patients (28 percent).</p><p>Some patients continue to have frequent episodes of acute pouchitis despite maintenance therapy with probiotics or antibiotics, and such patients have developed chronic antibiotic-refractory pouchitis. (See <a class="local">'Managing nonresponders'</a> below.)</p><p class="headingAnchor" id="H3136328027"><span class="h1">MANAGING NONRESPONDERS</span></p><p class="headingAnchor" id="H3136328046"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>Patients with pouchitis who do not have symptomatic improvement despite at least four weeks of antibiotic therapy are regarded as having chronic antibiotic-refractory pouchitis (CARP). Therapy for CARP is guided by pretreatment evaluation that includes (see  <a class="medical medical_review" href="/d/html/4073.html" rel="external">"Pouchitis: Epidemiology, pathogenesis, clinical features, and diagnosis"</a> and <a class="local">'Special populations'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Pouchoscopy with biopsy to reassess mucosal healing of the pouch following antibiotic therapy and to exclude infection (eg, cytomegalovirus).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory testing to confirm that secondary causes and coexisting conditions have been excluded (eg, infection, primary sclerosing cholangitis [PSC]). Blood tests include aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, celiac disease serology, antinuclear antibody, and immunoglobulin G4 (IgG4) level, and stool specimen for <em>Clostridioides difficile </em>is also obtained. (See  <a class="medical medical_review" href="/d/html/4771.html" rel="external">"Diagnosis of celiac disease in adults", section on 'Serologic evaluation'</a>.)</p><p></p><p class="bulletIndent1">Patients with elevated liver biochemical tests in a cholestatic pattern (predominantly elevated alkaline phosphatase) are evaluated for PSC with liver ultrasound or magnetic resonance cholangiopancreatography, and the diagnosis of PSC is discussed separately. (See  <a class="medical medical_review" href="/d/html/660.html" rel="external">"Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with CARP who report frequent bowel movements, straining, and/or a sense of incomplete evacuation should be evaluated for pouch outlet obstruction related to structural (eg, anastomotic stricture and distal pouch prolapse) or functional (eg, dyssynergic defecation) causes.  </p><p></p><p class="headingAnchor" id="H2602285909"><span class="h2">Immune-mediated chronic pouchitis</span><span class="headingEndMark"> — </span>Patients with CARP who do not have PSC, IgG4 disease, or a secondary cause for inflammatory changes of the pouch (eg, infection, ischemia, Crohn disease) are managed as immune-mediated CARP. (See  <a class="medical medical_review" href="/d/html/4073.html" rel="external">"Pouchitis: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p>The management approach for patients with CARP is generally similar to the management of ulcerative colitis (ie, induction and maintenance therapy) [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis"</a>.)</p><p class="headingAnchor" id="H2937237438"><span class="h3">Initial therapy</span><span class="headingEndMark"> — </span>Initial therapy for immune-mediated CARP is topical (rectal/pouch) <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> for four weeks [<a href="#rid38">38,39</a>]. Mesalamine is widely available in two forms: suppository or enema  (<a class="graphic graphic_table graphicRef86774" href="/d/graphic/86774.html" rel="external">table 1</a>). We typically use mesalamine suppository 1 g once daily or mesalamine enema 4 g once daily, and the dosing is similar to that used for patients with ulcerative proctitis. For patients without symptomatic relief (ie, decreased stool frequency) after two weeks of topical (rectal) mesalamine, we add oral mesalamine and continue topical mesalamine daily. We typically use oral mesalamine (ie, 2.4 to 4.8 g daily) for two to four weeks. </p><p>The use of <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> for chronic pouchitis has been supported by limited direct data and the author's experience. In an observational cohort of 10 patients with refractory pouchitis, oral or topical mesalamine was associated with clinical remission rates of 50 percent [<a href="#rid18">18</a>].</p><p>For patients with chronic pouchitis and coexisting arthritis, an alternative to oral <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> is <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> (2 to 4 g daily) and <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> (1 mg daily) [<a href="#rid40">40,41</a>]. Adverse effects of mesalamine and sulfasalazine and treatment of arthritis associated with inflammatory bowel disease are discussed separately. (See  <a class="medical medical_review" href="/d/html/111392.html" rel="external">"Treatment of arthritis associated with inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H2052655217"><span class="h3">Subsequent therapy</span><span class="headingEndMark"> — </span>For patients who do not have symptomatic improvement after four weeks of topical (rectal) and oral <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> therapy, subsequent options include  (<a class="graphic graphic_table graphicRef86774" href="/d/graphic/86774.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Begin topical (rectal) <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> (suppository, foam, enema) once daily for two weeks. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Begin topical (rectal) <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> (eg, foam, 2 mg per application) once daily for two weeks [<a href="#rid42">42,43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Begin oral <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> (9 mg daily for eight weeks). Oral budesonide is typically used for patients who have not improved with topical <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a>, oral mesalamine, and topical glucocorticoids. The dosing and pharmacology of budesonide is discussed separately. (See  <a class="medical medical_review" href="/d/html/4061.html" rel="external">"Overview of budesonide therapy for adults with inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1">An alternative to oral <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> is oral <a class="drug drug_general" data-topicid="9068" href="/d/drug information/9068.html" rel="external">beclomethasone</a> dipropionate (10 mg daily for eight weeks), but oral beclomethasone dipropionate is not widely available [<a href="#rid44">44,45</a>].</p><p></p><p>For example, for patients on <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> therapy who have some symptomatic improvement but without symptom resolution, we typically add a topical glucocorticoid or oral <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> while continuing mesalamine.</p><p>For patients who do not improve with <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> or glucocorticoids or who develop recurrent symptoms upon drug discontinuation, other options include biologic therapy. (See <a class="local">'Other options'</a> below.)</p><p>The use of topical and oral glucocorticoids for patients with CARP is based on limited published data and the author's experience [<a href="#rid42">42-44,46</a>]. In an observational study of 20 patients with antibiotic-refractory pouchitis who were treated with oral <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>, 15 patients (75 percent) achieved clinical remission based on Pouchitis Disease Activity Index (PDAI) score after eight weeks [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H846677590"><span class="h3">Other options</span><span class="headingEndMark"> — </span>For patients with immune-mediated chronic pouchitis who fail <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> and glucocorticoid therapy, we begin biologic therapy and typically use <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a> as first-line therapy, followed by <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a> as the second choice, and this approach is supported by guidelines [<a href="#rid14">14,47-49</a>].</p><p>We reserve anti-tumor necrosis factor (TNF) agents (eg, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>) as induction therapy for patients who fail <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a> and possibly <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a> [<a href="#rid14">14</a>]. The pretreatment evaluation, dosing, and administration of these agents for patients with chronic pouchitis are similar to the approach for patients with ulcerative colitis (UC), and this is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults"</a> and  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults"</a>.)</p><p>Most data on biologic agents for chronic pouchitis are based on few clinical trials and observational studies [<a href="#rid48">48,50,51</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">Vedolizumab</a> – Vedolizumab, a gut-selective anti-integrin agent, has been associated with symptom and endoscopic improvement in chronic pouchitis [<a href="#rid7">7,48,51,52</a>]. In a systematic review of seven studies including 44 patients with chronic pouchitis who were treated with vedolizumab, 33 patients (75 percent) had symptomatic improvement at 12 weeks, and 28 of 38 patients (74 percent) had endoscopic improvement at six months [<a href="#rid48">48</a>]. In a randomized trial including 102 patients with active chronic pouchitis, vedolizumab resulted in higher rates of combined clinical and endoscopic remission as measured by the modified PDAI compared with placebo after 14 weeks (31 versus 10 percent) [<a href="#rid51">51</a>]. Vedolizumab also resulted in higher rates of sustained remission after 34 weeks (35 versus 18 percent). Rates of serious adverse events were numerically similar between groups. (See <a class="local">'Treatment goals'</a> above and  <a class="medical medical_review" href="/d/html/4073.html" rel="external">"Pouchitis: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Scoring systems for assessing disease activity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">Ustekinumab</a> – The use of ustekinumab, an anti-interleukin 12/23 antibody, for chronic pouchitis is supported mainly by case series [<a href="#rid8">8,47,50,53,54</a>]. In a study including 24 patients with CARP with a median follow-up time of 13 months, 12 patients (50 percent) had symptomatic response and four of nine patients (44 percent) had endoscopic improvement [<a href="#rid47">47</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-TNF agents – The use of anti-TNF agents for chronic pouchitis may be limited by precolectomy exposure to the drug [<a href="#rid52">52,55-59</a>]. In a study including 23 patients with chronic pouchitis who were treated with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, 10 patients (44 percent) achieved clinical remission at 14 weeks of therapy [<a href="#rid52">52</a>]. Adverse events associated with infliximab (eg, infusion reactions, hypersensitivity) led to discontinuation of the drug in nine patients (39 percent), possibly due to immunogenicity in patients with prior exposure to anti-TNF agents. In a cohort of 13 patients with chronic pouchitis who were treated with <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, five patients (39 percent) achieved clinical remission at 14 weeks [<a href="#rid52">52</a>]. In a small trial comparing adalimumab with placebo in 13 patients with refractory pouchitis, there were no statistically significant differences in rates of improved PDAI scores between groups [<a href="#rid59">59</a>].</p><p></p><p>Although patients with pouchitis who were nonresponders to a specific biologic agent prior to colectomy can be treated with the same biologic agent after surgery, use of the prior biologic agent has been associated with an increased risk for treatment failure [<a href="#rid14">14,60</a>].</p><p>Patients with chronic pouchitis who fail medical therapy and whose quality of life is significantly compromised may be referred to a colorectal surgeon for consideration of surgical intervention (eg, fecal diversion with ileostomy). Risk of pouch failure is discussed separately. (See  <a class="medical medical_review" href="/d/html/15017.html" rel="external">"Restorative proctocolectomy with ileal pouch-anal anastomosis: Laparoscopic approach"</a> and  <a class="medical medical_review" href="/d/html/1375.html" rel="external">"Surgical management of ulcerative colitis", section on 'Surgical complications'</a>.)  </p><p class="headingAnchor" id="H2577071794"><span class="h3">Investigational therapies</span><span class="headingEndMark"> — </span>Therapies that have been studied for treating CARP but remain investigational include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">Tofacitinib</a> – Several case reports have shown that the small molecule tofacitinib was effective for treating patients with CARP who have failed anti-TNF agents, anti-interleukin agents, or anti-integrin agents [<a href="#rid61">61,62</a>]. Tofacitinib therapy for patients with UC is discussed separately. (See  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Janus kinase (JAK) inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous immunoglobulin – In a small case series of 16 patients with refractory pouchitis, intravenous immunoglobulin infusion was associated with clinical and endoscopic improvement as measured by the modified PDAI [<a href="#rid63">63</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperbaric oxygen therapy (HBOT) – Data from case series suggested that HBOT was beneficial for some patients with chronic inflammatory disorders of the pouch [<a href="#rid64">64-67</a>]. In a systemic review of 19 studies including 60 patients with pouch disorders, HBOT was associated with clinical remission rates of 31 percent [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> – Oral vancomycin is a standard therapy for <em>Clostridioides</em> <em>difficile</em> infection in pouch patients [<a href="#rid68">68</a>]. In addition, case reports suggested that oral vancomycin had therapeutic effects for PSC-associated pouchitis and enteritis [<a href="#rid69">69-71</a>]. In a case series of 41 patients with pouch disorders, oral vancomycin was associated clinical response in 21 patients (51 percent) after four weeks of therapy and sustained clinical response at three and six months in 16 of 21 responders (76 percent) [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Topical alicaforsen – Data on topical application of alicaforsen for treating CARP are mixed [<a href="#rid73">73,74</a>]. In an observational study including 12 patients with CARP, treatment with alicaforsen enema for six weeks was associated with clinical improvement as measured by reduction in PDAI score [<a href="#rid74">74</a>]. However, in a subsequent trial, there was no statistically significant improvement with alicaforsen enema in patients with pouchitis [<a href="#rid75">75</a>]. Alicaforsen is an antisense inhibitor of intercellular adhesion molecule-1 oligonucleotide.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> – In an observational study of 10 patients with antibiotic-refractory pouchitis, topical tacrolimus for eight weeks was shown to reduce symptom, endoscopy, and histology scores [<a href="#rid76">76</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Therapies of no or uncertain benefit – Fecal microbiota transplantation (FMT) has been studied for treating non-<em>Clostridioides difficile </em>infection; however efficacy has not been established [<a href="#rid77">77-85</a>]. The use of FMT for treating <em>Clostridioides difficile </em>infection is discussed separately. (See  <a class="medical medical_review" href="/d/html/2604.html" rel="external">"Fecal microbiota transplantation for treatment of <i>Clostridioides difficile</i> infection"</a>.)</p><p></p><p class="bulletIndent1">Butyrate and <a class="drug drug_general" data-topicid="8747" href="/d/drug information/8747.html" rel="external">glutamine</a> suppositories [<a href="#rid86">86</a>] and bismuth carbomer foam [<a href="#rid87">87</a>] have been studied for treating chronic pouchitis, but their efficacy has not been established. </p><p></p><p class="headingAnchor" id="H59921307"><span class="h1">SPECIAL POPULATIONS</span><span class="headingEndMark"> — </span>Inflammatory pouch disorders are not limited to acute pouchitis. Consensus guidelines from the International Ileal Pouch Consortium on the classification of ileal pouch disorders will help standardize terminology and classification of disease phenotypes, predict prognosis, and guide medical, endoscopic, and surgical therapies [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H3238035389"><span class="h2">Pregnant patients</span><span class="headingEndMark"> — </span>The incidence of acute pouchitis in pregnant patients is uncertain, although pregnancy does not appear to be a risk factor for developing pouchitis [<a href="#rid88">88</a>]. In a systematic review of 283 pregnancies, postpartum pouchitis was reported in approximately 2 percent of patients [<a href="#rid89">89</a>]. Management of pouchitis during pregnancy includes an assessment of possible risks associated with abdominal and pelvic imaging, pouchoscopy, and medication use. Input from a multidisciplinary team is required for some patients. (See  <a class="medical medical_review" href="/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a>.)</p><p>Therapeutic options for pregnant patients include penicillin-based antibiotics (eg, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>/clavulanic acid) or <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>. We avoid the use of quinolones and nitroimidazoles during pregnancy, especially during the first trimester [<a href="#rid14">14</a>]. The use of glucocorticoids, immunomodulators, and biologic agents in pregnant patients with pouchitis is similar to their use in pregnant patients with inflammatory bowel disease, and this is discussed separately [<a href="#rid90">90-92</a>]. (See  <a class="medical medical_review" href="/d/html/4083.html" rel="external">"Fertility, pregnancy, and nursing in inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H2204818148"><span class="h2">PSC-associated chronic pouchitis</span><span class="headingEndMark"> — </span>Patients with an ileal pouch and underlying primary sclerosing cholangitis (PSC) are at higher risk for chronic antibiotic-refractory pouchitis (CARP), and patients with PSC-associated chronic pouchitis are generally managed with therapies that target mucosal inflammation in the pouch body and afferent limb. PSC-associated pouchitis and enteritis are considered a distinct phenotype with unique clinical, endoscopic, and histologic features, treatment response, and risk of neoplasia [<a href="#rid1">1,93-95</a>]. The diagnosis of PSC is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/660.html" rel="external">"Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p>Patients with ileal pouch and coexisting PSC commonly have endoscopic and/or histologic inflammation of the pouch body, afferent limb, and cuff [<a href="#rid93">93</a>]. The author has also observed that patients often have mild symptoms in the presence of marked pouch inflammation and a long segment of enteritis (&gt;10 cm). On endoscopy, the pouch inlet shows a patulous appearance. Patients with PSC-associated pouchitis are typically given antibiotic therapy initially while oral <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> is an alternative option. (See <a class="local">'Acute idiopathic pouchitis'</a> above and <a class="local">'Immune-mediated chronic pouchitis'</a> above.).</p><p>For patients with PSC who do not respond to initial therapy, we typically use an eight-week course of oral <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> (9 mg daily) or budesonide enema or foam daily [<a href="#rid42">42,96</a>]. Because symptomatic and endoscopic relapse is common, patients who respond to oral budesonide may require maintenance therapy with the same agent at a lower dose (eg, oral budesonide 3 mg daily). Dosing and adverse effects of budesonide are discussed separately. (See  <a class="medical medical_review" href="/d/html/4061.html" rel="external">"Overview of budesonide therapy for adults with inflammatory bowel disease", section on 'Dosing'</a>.) </p><p>For some patients who fail <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>, the author has observed that oral <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> (500 to 1000 mg daily) may be beneficial for treating both pouchitis and enteritis [<a href="#rid69">69-71</a>].</p><p>For patients who achieved clinical remission with glucocorticoids, an alternative approach for maintenance therapy is to use an immunomodulator (eg, oral <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a> [6-MP] 25 to 50 mg daily or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> 7.5 to 12.5 mg subcutaneously weekly). Pretreatment evaluation, dosing, and monitoring for immunomodulators are discussed separately. (See  <a class="medical medical_review" href="/d/html/4056.html" rel="external">"Overview of azathioprine and mercaptopurine use in inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a>.) </p><p>Data on managing PSC-associated pouchitis and enteritis with biologic agents are limited. <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">Vedolizumab</a> is an option for patients with PSC-associated pouchitis and enteritis [<a href="#rid97">97</a>]. In studies on the use of other biologic agents (eg, <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a>, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>) for CARP and other inflammatory disorders of the pouch, some of the study participants had concurrent PSC, but subgroup analyses were not reported. (See <a class="local">'Other options'</a> above.)</p><p class="headingAnchor" id="H3619781440"><span class="h2">IgG4-associated chronic pouchitis</span><span class="headingEndMark"> — </span>Patients with immunoglobulin G4 (IgG4)-related pouchitis are at higher risk for antibiotic-refractory pouchitis, and such patients are primarily managed with therapies that target mucosal inflammation [<a href="#rid98">98,99</a>]. (See  <a class="medical medical_review" href="/d/html/121219.html" rel="external">"Treatment and prognosis of IgG4-related disease"</a>.) </p><p>Initial therapy is typically oral <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> (9 mg daily) for eight weeks [<a href="#rid100">100</a>]. (See  <a class="medical medical_review" href="/d/html/4061.html" rel="external">"Overview of budesonide therapy for adults with inflammatory bowel disease"</a>.)</p><p>For patients who fail <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> or who relapse with discontinuation, other options include low dose immunomodulator (eg, 6-MP 50 mg daily). Pretreatment evaluation, dosing, and monitoring for immunomodulators are discussed separately. (See  <a class="medical medical_review" href="/d/html/4056.html" rel="external">"Overview of azathioprine and mercaptopurine use in inflammatory bowel disease"</a>.) </p><p class="headingAnchor" id="H1161433871"><span class="h2">Patients with prepouch enteritis or ileitis</span><span class="headingEndMark"> — </span>Prepouch ileitis represents a spectrum of inflammatory disorders ranging from nonsteroidal antiinflammatory drug (NSAID)-induced enteritis to immune-mediated pouchitis to Crohn disease of the pouch [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/d/html/4073.html" rel="external">"Pouchitis: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p>Patients with pouchitis and coexisting prepouch ileitis (≥10 cm) may be initially treated with antibiotics or oral <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>, 9 mg daily for eight weeks, followed by 3 mg daily for maintenance therapy. Pharmacology and safety of budesonide for patients with inflammatory bowel disease is discussed separately. (See  <a class="medical medical_review" href="/d/html/4061.html" rel="external">"Overview of budesonide therapy for adults with inflammatory bowel disease"</a>.) </p><p>An alternative to oral <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> is oral <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> (2 to 4 g daily) or mesalamine enemas daily  (<a class="graphic graphic_table graphicRef86774" href="/d/graphic/86774.html" rel="external">table 1</a>). Biologic agents have been studied, but failed to achieve remission in most patients [<a href="#rid102">102</a>]. </p><p>Prepouch ileitis associated with Crohn disease is treated similarly to the inflammatory Crohn disease of the pouch [<a href="#rid14">14</a>]. (See <a class="local">'Crohn disease of the pouch'</a> below.) </p><p class="headingAnchor" id="H2153240877"><span class="h2">Crohn disease of the pouch</span><span class="headingEndMark"> — </span>Crohn disease of the pouch can be classified into inflammatory, fibrostenotic, or fistulizing phenotype [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/4073.html" rel="external">"Pouchitis: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p>Studies on therapy for Crohn disease of the pouch are limited [<a href="#rid8">8,9,55,57</a>]. Principles for treating Crohn disease of the pouch that were endorsed by the International Ileal Pouch Consortium include [<a href="#rid14">14</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Antibiotics may be an adjunct to induction therapy for Crohn disease.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral or topical <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> is an option for induction therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biologics (eg, anti-tumor necrosis factor (TNF) agents, <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a>, <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a>) and small molecules (eg, <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a>) are options for treating inflammatory or penetrating Crohn disease of the pouch [<a href="#rid103">103</a>]. Immunomodulators can be used as monotherapy or in combination with anti-TNF agents for maintenance therapy in inflammatory or penetrating Crohn disease of the pouch. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Loss of response to biologic therapy before colectomy in patients with inflammatory bowel disease does not prohibit using the same agent for treating Crohn disease of the pouch, provided that the patient did not develop anti-drug antibodies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While endoscopic (eg, balloon dilation, endoscopic stricturotomy) and/or surgical (eg, stricturoplasty, resection and anastomosis) interventions are often used for fibrotic Crohn disease of the pouch, medical therapy (eg, glucocorticoids, biologics) is an alternative, especially for inflammatory strictures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The following therapies are not routinely used: <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> (oral or topical) or, for patients with indeterminate colitis, prophylaxis against the developing Crohn disease. </p><p></p><p class="headingAnchor" id="H2931843587"><span class="h2">Cuffitis</span><span class="headingEndMark"> — </span>Classic cuffitis is a recurrence of ulcerative colitis in the residual cuff of rectal mucosa following proctocolectomy with ileal pouch-anal anastomosis. (See  <a class="medical medical_review" href="/d/html/4073.html" rel="external">"Pouchitis: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p>Cuffitis is treated with topical (rectal) <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> (suppository or enema) or topical (rectal) glucocorticosteroid (eg, <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> suppository or <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> foam 2 mg once a day)  (<a class="graphic graphic_table graphicRef86774" href="/d/graphic/86774.html" rel="external">table 1</a>) [<a href="#rid39">39,104</a>]. Some patients with cuffitis may benefit from maintenance therapy with the topical agents, whereas others may have a limited response to topical therapy. Thus, cuffitis is classified into (topical) mesalamine or glucocorticoid-responsive, glucocorticoid-dependent, or glucocorticoid-refractory [<a href="#rid1">1</a>]. Classic cuffitis usually responds to topical therapy, whereas non-classic cuffitis can result from other etiologies (eg, Crohn disease) that may respond to targeted therapy [<a href="#rid1">1,14</a>]. </p><p class="headingAnchor" id="H3528816152"><span class="h2">Ischemia-associated pouchitis</span><span class="headingEndMark"> — </span>Among nonsurgical therapies for ischemic pouchitis, hyperbaric oxygen therapy may be beneficial [<a href="#rid14">14,64-66</a>]. However, ischemic pouchitis responds poorly to antibiotic therapy [<a href="#rid105">105</a>].</p><p class="headingAnchor" id="H863639502"><span class="h2">Fecal stasis-associated pouchitis</span><span class="headingEndMark"> — </span>Fecal stasis-associated pouchitis may be more common in patients with underlying familial adenomatous polyposis [<a href="#rid106">106</a>]. Based on clinical experience, therapy for structural (eg, endoscopic balloon dilation of anastomotic stricture) or functional (eg, biofeedback) pouch outlet disorders often results in improvement of pouch inflammation. (See  <a class="medical medical_review" href="/d/html/2636.html" rel="external">"Management of chronic constipation in adults", section on 'Biofeedback'</a>.)</p><p class="headingAnchor" id="H3819131396"><span class="h2">Diversion pouchitis</span><span class="headingEndMark"> — </span>Medical therapy for diversion pouchitis is similar to therapy for diversion colitis, and this is discussed separately. </p><p class="headingAnchor" id="H2228564230"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/130096.html" rel="external">"Society guideline links: Pouchitis"</a>.)</p><p class="headingAnchor" id="H3136328109"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of disease </strong>– Pouchitis is an inflammatory condition of the ileal pouch reservoir of an ileal pouch-anal anastomosis. Pouchitis has been classified based on disease characteristics such as the duration of symptoms, response to antibiotics, frequency of flares, etiology, and disease activity. Most patients with an ileal pouch have some degree of endoscopic or histologic inflammation, and pouchitis likely represents a disease spectrum with a range of presentations that may evolve over time. (See <a class="local">'Spectrum of disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment goals </strong>– Goals of therapy for patients with acute pouchitis are to alleviate symptoms and to achieve clinical and endoscopic remission by demonstrating mucosal healing. Histologic improvement (ie, resolution of acute inflammatory cell infiltrate) is emerging as an additional component of disease remission. Assessing treatment response for patients with pouchitis includes recognizing that the normal stool pattern is typically four to seven formed stools daily without seepage. (See <a class="local">'Treatment goals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy </strong>– For patients with acute idiopathic pouchitis, we suggest initial therapy with <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> rather than other antibiotics or observation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically use ciprofloxacin 500 mg every 12 hours for two weeks, while alternatives to ciprofloxacin include <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> or <a class="drug drug_general" data-topicid="10205" href="/d/drug information/10205.html" rel="external">tinidazole</a> since these agents have also been associated with symptomatic improvement  (<a class="graphic graphic_algorithm graphicRef129598" href="/d/graphic/129598.html" rel="external">algorithm 1</a>). (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent management </strong>– For patients with acute idiopathic pouchitis who do not respond to initial antibiotic treatment, we perform stool culture and susceptibility testing of bacterial flora and select a single active antibiotic based on those results for a four-week course. If such testing is not available, we suggest empiric, dual antibiotic therapy rather than antibiotic monotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically use <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> combined with <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> or <a class="drug drug_general" data-topicid="10205" href="/d/drug information/10205.html" rel="external">tinidazole</a> or <a class="drug drug_general" data-topicid="10202" href="/d/drug information/10202.html" rel="external">rifaximin</a> for four weeks. (See <a class="local">'Subsequent management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance therapy </strong>– For patients with pouchitis who respond to antibiotic therapy but who relapse ≥3 times per year or who required ≥4 weeks of antibiotic therapy to achieve remission, we suggest maintenance probiotic therapy rather than no maintenance or chronic antibiotic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically use the probiotic VSL#3; however, chronic antibiotic therapy (eg, <a class="drug drug_general" data-topicid="10202" href="/d/drug information/10202.html" rel="external">rifaximin</a> daily) is an alternative option. (See <a class="local">'Managing relapse'</a> above and  <a class="medical medical_review" href="/d/html/2603.html" rel="external">"Probiotics for gastrointestinal diseases"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Managing nonresponders </strong>– Patients with pouchitis who do not have symptomatic improvement despite at least four weeks of antibiotic therapy are regarded as having chronic antibiotic-refractory pouchitis. After confirming that secondary causes of pouchitis have been excluded, we suggest initial management with topical (rectal) <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> rather than further antibiotics (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If there is no symptomatic improvement in two weeks, we add oral mesalamine. For patients who do not respond after four weeks of topical and oral mesalamine, subsequent options include topical or oral glucocorticoids (eg, <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>) or a biologic agent (eg, <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a>). (See <a class="local">'Managing nonresponders'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance </strong>– The approach to surveillance for patients with inflammatory bowel disease including those with an ileal pouch is discussed separately. (See  <a class="medical medical_review" href="/d/html/4079.html" rel="external">"Surveillance and management of dysplasia in patients with inflammatory bowel disease"</a>.)</p><p></p><p class="headingAnchor" id="H3136328116"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Dr. Mark Peppercorn, who contributed to an earlier version of this topic review.</p><p>The UpToDate editorial staff acknowledges Paul Rutgeerts, MD (deceased), who contributed as a section editor for UpToDate in Gastroenterology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Shen B, Kochhar GS, Kariv R, et al. Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol 2021; 6:826.</a></li><li><a class="nounderline abstract_t">Kayal M, Plietz M, Radcliffe M, et al. Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis. Aliment Pharmacol Ther 2019; 50:1189.</a></li><li><a class="nounderline abstract_t">Shen B, Achkar JP, Connor JT, et al. Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum 2003; 46:748.</a></li><li><a class="nounderline abstract_t">Shen B, Achkar JP, Lashner BA, et al. Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 2001; 121:261.</a></li><li><a class="nounderline abstract_t">Athayde J, Davies SC, Parker CE, et al. Placebo Rates in Randomized Controlled Trials of Pouchitis Therapy. Dig Dis Sci 2018; 63:2519.</a></li><li><a class="nounderline abstract_t">Zhu H, Wu XR, Queener E, et al. Clinical value of surveillance pouchoscopy in asymptomatic ileal pouch patients with underlying inflammatory bowel disease. Surg Endosc 2013; 27:4325.</a></li><li><a class="nounderline abstract_t">Gregory M, Weaver KN, Hoversten P, et al. Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort. Inflamm Bowel Dis 2019; 25:1569.</a></li><li><a class="nounderline abstract_t">Weaver KN, Gregory M, Syal G, et al. Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort. Inflamm Bowel Dis 2019; 25:767.</a></li><li><a class="nounderline abstract_t">Li Y, Lopez R, Queener E, Shen B. Adalimumab therapy in Crohn's disease of the ileal pouch. Inflamm Bowel Dis 2012; 18:2232.</a></li><li><a class="nounderline abstract_t">Achkar JP, Al-Haddad M, Lashner B, et al. Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol 2005; 3:60.</a></li><li><a class="nounderline abstract_t">Nguyen N, Zhang B, Holubar SD, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2019; 5:CD001176.</a></li><li><a class="nounderline abstract_t">Fliss Isakov N, Kornblum J, Zemel M, et al. The Effect of the Crohn's Disease Exclusion Diet on Patients With Pouch Inflammation: An Interventional Pilot Study. Clin Gastroenterol Hepatol 2023; 21:1654.</a></li><li><a class="nounderline abstract_t">Godny L, Maharshak N, Reshef L, et al. Fruit Consumption is Associated with Alterations in Microbial Composition and Lower Rates of Pouchitis. J Crohns Colitis 2019; 13:1265.</a></li><li><a class="nounderline abstract_t">Shen B, Kochhar GS, Rubin DT, et al. Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol 2022; 7:69.</a></li><li><a class="nounderline abstract_t">Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7:301.</a></li><li><a class="nounderline abstract_t">Ha CY, Bauer JJ, Lazarev M, et al. Early institution of tinidazole may prevent pouchitis following ileal pouch anal anastomosis (IPAA) surgery in ulcerative colitis (UC) patients. Gastroenterology 2010; 138 Suppl:S69.</a></li><li><a class="nounderline abstract_t">Hurst RD, Molinari M, Chung TP, et al. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996; 131:497.</a></li><li><a class="nounderline abstract_t">Shen B, Fazio VW, Remzi FH, et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum 2007; 50:498.</a></li><li><a class="nounderline abstract_t">McLaughlin SD, Clark SK, Shafi S, et al. Fecal coliform testing to identify effective antibiotic therapies for patients with antibiotic-resistant pouchitis. Clin Gastroenterol Hepatol 2009; 7:545.</a></li><li><a class="nounderline abstract_t">Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999; 13:713.</a></li><li><a class="nounderline abstract_t">Abdelrazeq AS, Kelly SM, Lund JN, Leveson SH. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis 2005; 7:182.</a></li><li><a class="nounderline abstract_t">Mimura T, Rizzello F, Helwig U, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002; 16:909.</a></li><li><a class="nounderline abstract_t">Bar N, Avraham Y, Dubinsky V, et al. Long-term Antibiotic Treatment in Pouchitis-Patterns of Use and Safety. Inflamm Bowel Dis 2022; 28:1027.</a></li><li><a class="nounderline abstract_t">Dubinsky V, Reshef L, Bar N, et al. Predominantly Antibiotic-resistant Intestinal Microbiome Persists in Patients With Pouchitis Who Respond to Antibiotic Therapy. Gastroenterology 2020; 158:610.</a></li><li><a class="nounderline abstract_t">Fukushima K, Saito T, Kohyama A, Watanabe K. Increased Quinolone-Resistant Mutations of gyrA and parC Genes after Pouchitis Treatment with Ciprofloxacin. Dig Surg 2020; 37:321.</a></li><li><a class="nounderline abstract_t">Ben-Bassat O, Tyler AD, Xu W, et al. Ileal pouch symptoms do not correlate with inflammation of the pouch. Clin Gastroenterol Hepatol 2014; 12:831.</a></li><li><a class="nounderline abstract_t">Sedano R, Ma C, Pai RK, et al. An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. Aliment Pharmacol Ther 2021; 53:1108.</a></li><li><a class="nounderline abstract_t">Lohmuller JL, Pemberton JH, Dozois RR, et al. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg 1990; 211:622.</a></li><li><a class="nounderline abstract_t">Komanduri S, Gillevet PM, Sikaroodi M, et al. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol 2007; 5:352.</a></li><li class="breakAll">VSL#3. National Institutes of Health, Office of Dietary Supplements. Date added: May 24, 2017. https://dsld.od.nih.gov/label/73496 (Accessed on June 15, 2022).</li><li><a class="nounderline abstract_t">Palumbo P, Lombardi F, Cifone MG, Cinque B. The Epithelial Barrier Model Shows That the Properties of VSL#3 Depend from Where it is Manufactured. Endocr Metab Immune Disord Drug Targets 2019; 19:199.</a></li><li><a class="nounderline abstract_t">Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305.</a></li><li><a class="nounderline abstract_t">Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005; 22:721.</a></li><li><a class="nounderline abstract_t">Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53:108.</a></li><li><a class="nounderline abstract_t">McLaughlin SD, Johnson MW, Clark SK, et al. VSL#3 for chronic pouchitis: experience in UK clinical practice. Gastroenterology 2008; 134 Suppl 1:A711.</a></li><li><a class="nounderline abstract_t">Shen B, Remzi FH, Lopez AR, Queener E. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol 2008; 8:26.</a></li><li><a class="nounderline abstract_t">Segal JP, Poo SX, McLaughlin SD, et al. Long-term follow-up of the use of maintenance antibiotic therapy for chronic antibiotic-dependent pouchitis. Frontline Gastroenterol 2018; 9:154.</a></li><li><a class="nounderline abstract_t">Miglioli M, Barbara L, Di Febo G, et al. Topical administration of 5-aminosalicylic acid: a therapeutic proposal for the treatment of pouchitis. N Engl J Med 1989; 26:320.</a></li><li><a class="nounderline abstract_t">Wu B, Lian L, Li Y, et al. Clinical course of cuffitis in ulcerative colitis patients with restorative proctocolectomy and ileal pouch-anal anastomoses. Inflamm Bowel Dis 2013; 19:404.</a></li><li><a class="nounderline abstract_t">Belluzzi A, Serrani M, Roda G, et al. Pilot study: the use of sulfasalazine for the treatment of acute pouchitis. Aliment Pharmacol Ther 2010; 31:228.</a></li><li><a class="nounderline abstract_t">Scaioli E, Sartini A, Liverani E, et al. Sulfasalazine in Prevention of Pouchitis After Proctocolectomy with Ileal Pouch-Anal Anastomosis for Ulcerative Colitis. Dig Dis Sci 2017; 62:1016.</a></li><li><a class="nounderline abstract_t">Sambuelli A, Boerr L, Negreira S, et al. Budesonide enema in pouchitis--a double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther 2002; 16:27.</a></li><li><a class="nounderline abstract_t">Hibi T, Naganuma M, Oda E, et al. Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials. Intest Res 2020; 18:56.</a></li><li><a class="nounderline abstract_t">Gionchetti P, Calabrese C, Calafiore A, et al. Oral beclomethasone dipropionate in chronic refractory pouchitis. J Crohns Colitis 2014; 8:649.</a></li><li class="breakAll">https://www.medicines.org.uk/emc/product/6417 (Accessed on July 23, 2020).</li><li><a class="nounderline abstract_t">Gionchetti P, Rizzello F, Poggioli G, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007; 25:1231.</a></li><li><a class="nounderline abstract_t">Ollech JE, Rubin DT, Glick L, et al. Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. Dig Dis Sci 2019; 64:3596.</a></li><li><a class="nounderline abstract_t">Ribaldone DG, Pellicano R, Saracco GM, et al. Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis. Rev Esp Enferm Dig 2020; 112:59.</a></li><li><a class="nounderline abstract_t">Dalal RS, Gupta S, Goodrick H, et al. Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders. Inflamm Bowel Dis 2022; 28:146.</a></li><li><a class="nounderline abstract_t">Chandan S, Mohan BP, Kumar A, et al. Safety and Efficacy of Biological Therapy in Chronic Antibiotic Refractory Pouchitis: A Systematic Review With Meta-analysis. J Clin Gastroenterol 2021; 55:481.</a></li><li><a class="nounderline abstract_t">Travis S, Silverberg MS, Danese S, et al. Vedolizumab for the Treatment of Chronic Pouchitis. N Engl J Med 2023; 388:1191.</a></li><li><a class="nounderline abstract_t">Verstockt B, Claeys C, De Hertogh G, et al. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience. United European Gastroenterol J 2019; 7:1215.</a></li><li><a class="nounderline abstract_t">Tomasz B, Zoran S, Jarosław W, et al. Long-term use of probiotics Lactobacillus and Bifidobacterium has a prophylactic effect on the occurrence and severity of pouchitis: a randomized prospective study. Biomed Res Int 2014; 2014:208064.</a></li><li><a class="nounderline abstract_t">Rocchi C, Soliman YY, Massidda M, et al. Is Ustekinumab Effective in Refractory Crohn's Disease of the Pouch and Chronic Pouchitis? A Systematic Review. Dig Dis Sci 2022; 67:1948.</a></li><li><a class="nounderline abstract_t">Haveran LA, Sehgal R, Poritz LS, et al. Infliximab and/or azathioprine in the treatment of Crohn's disease-like complications after IPAA. Dis Colon Rectum 2011; 54:15.</a></li><li><a class="nounderline abstract_t">Barreiro-de Acosta M, García-Bosch O, Gordillo J, et al. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. Eur J Gastroenterol Hepatol 2012; 24:756.</a></li><li><a class="nounderline abstract_t">Ferrante M, D'Haens G, Dewit O, et al. Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series. Inflamm Bowel Dis 2010; 16:243.</a></li><li><a class="nounderline abstract_t">Barreiro-de Acosta M, García-Bosch O, Souto R, et al. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study. Inflamm Bowel Dis 2012; 18:812.</a></li><li><a class="nounderline abstract_t">Kjær MD, Qvist N, Nordgaard-Lassen I, et al. Adalimumab in the treatment of chronic pouchitis. A randomized double-blind, placebo-controlled trial. Scand J Gastroenterol 2019; 54:188.</a></li><li><a class="nounderline abstract_t">Kayal M, Lambin T, Plietz M, et al. Recycling of Precolectomy Anti-Tumor Necrosis Factor Agents in Chronic Pouch Inflammation Is Associated With Treatment Failure. Clin Gastroenterol Hepatol 2021; 19:1491.</a></li><li><a class="nounderline abstract_t">Okano S, Yoshimura N, Sako M, Takazoe M. A case of refractory chronic pouchitis successfully treated with tofacitinib. Clin J Gastroenterol 2020; 13:560.</a></li><li><a class="nounderline abstract_t">Weisshof R, Aharoni Golan M, Sossenheimer PH, et al. Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci 2019; 64:1945.</a></li><li><a class="nounderline abstract_t">Horton N, Kochhar G, Patel K, et al. Efficacy and Factors Associated with Treatment Response of Intravenous Immunoglobulin in Inpatients with Refractory Inflammatory Bowel Diseases. Inflamm Bowel Dis 2017; 23:1080.</a></li><li><a class="nounderline abstract_t">Nyabanga CT, Kulkarni G, Shen B. Hyperbaric oxygen therapy for chronic antibiotic-refractory ischemic pouchitis. Gastroenterol Rep (Oxf) 2015.</a></li><li><a class="nounderline abstract_t">Hasan B, Yim Y, Ur Rashid M, et al. Hyperbaric Oxygen Therapy in Chronic Inflammatory Conditions of the Pouch. Inflamm Bowel Dis 2021; 27:965.</a></li><li><a class="nounderline abstract_t">Fahad H, Dulai PS, Shen B, Kochhar GS. Hyperbaric Oxygen Therapy Is Effective in the Treatment of Inflammatory and Fistulizing Pouch Complications. Clin Gastroenterol Hepatol 2021; 19:1288.</a></li><li><a class="nounderline abstract_t">McCurdy J, Siw KCK, Kandel R, et al. The Effectiveness and Safety of Hyperbaric Oxygen Therapy in Various Phenotypes of Inflammatory Bowel Disease: Systematic Review With Meta-analysis. Inflamm Bowel Dis 2022; 28:611.</a></li><li><a class="nounderline abstract_t">Kayal M, Tixier E, Plietz M, et al. Clostridioides Difficile Infection Is a Rare Cause of Infectious Pouchitis. Inflamm Intest Dis 2020; 5:59.</a></li><li><a class="nounderline abstract_t">Thind K, Shen B, Farooqi R. Vancomycin in treatment of immune-mediated pouchitis. Am J Gastroenterol 2018; 113:S1180.</a></li><li class="breakAll">Shen B. Chapter 29-Medical treatment of pouchitis. In: Pouchitis and Ileal Pouch Disorders, Shen B (Ed), Academic Press, Cambridge 2019.</li><li><a class="nounderline abstract_t">Shen B. Oral vancomycin in the treatment of primary sclerosing cholangitis-associated pouchitis. Gastroenterol Rep (Oxf) 2021; 9:274.</a></li><li><a class="nounderline abstract_t">Lupu G, Weaver KN, Herfarth HH, Barnes EL. Vancomycin Is Effective in the Treatment of Chronic Inflammatory Conditions of the Pouch. Inflamm Bowel Dis 2022; 28:1610.</a></li><li><a class="nounderline abstract_t">Greuter T, Biedermann L, Rogler G, et al. Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series. United European Gastroenterol J 2016; 4:97.</a></li><li><a class="nounderline abstract_t">Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004; 19:281.</a></li><li class="breakAll">Atlantic Healthcare. Atlantic Healthcare announces results from phase 3 trial of alicaforsen enema for orphan-designated pouchitis. July 31, 2019. https://www.atlantichc.com/atlantic-healthcareannounces-results-from-phase-3-trial-of-alicaforsen-enema-fororphan-designated-pouchitis/ (Accessed on October 02, 2021).</li><li><a class="nounderline abstract_t">Uchino M, Ikeuchi H, Matsuoka H, et al. Topical tacrolimus therapy for antibiotic-refractory pouchitis. Dis Colon Rectum 2013; 56:1166.</a></li><li><a class="nounderline abstract_t">Nishida A, Imaeda H, Inatomi O, et al. The efficacy of fecal microbiota transplantation for patients with chronic pouchitis: A case series. Clin Case Rep 2019; 7:782.</a></li><li><a class="nounderline abstract_t">Kousgaard SJ, Michaelsen TY, Nielsen HL, et al. Clinical results and microbiota changes after faecal microbiota transplantation for chronic pouchitis: a pilot study. Scand J Gastroenterol 2020; 55:421.</a></li><li><a class="nounderline abstract_t">Selvig D, Piceno Y, Terdiman J, et al. Fecal Microbiota Transplantation in Pouchitis: Clinical, Endoscopic, Histologic, and Microbiota Results from a Pilot Study. Dig Dis Sci 2020; 65:1099.</a></li><li><a class="nounderline abstract_t">Landy J, Walker AW, Li JV, et al. Variable alterations of the microbiota, without metabolic or immunological change, following faecal microbiota transplantation in patients with chronic pouchitis. Sci Rep 2015; 5:12955.</a></li><li><a class="nounderline abstract_t">Fang S, Kraft CS, Dhere T, et al. Successful treatment of chronic Pouchitis utilizing fecal microbiota transplantation (FMT): a case report. Int J Colorectal Dis 2016; 31:1093.</a></li><li><a class="nounderline abstract_t">Herfarth H, Barnes EL, Long MD, et al. Combined Endoscopic and Oral Fecal Microbiota Transplantation in Patients with Antibiotic-Dependent Pouchitis: Low Clinical Efficacy due to Low Donor Microbial Engraftment. Inflamm Intest Dis 2019; 4:1.</a></li><li><a class="nounderline abstract_t">Karjalainen EK, Renkonen-Sinisalo L, Satokari R, et al. Fecal Microbiota Transplantation in Chronic Pouchitis: A Randomized, Parallel, Double-Blinded Clinical Trial. Inflamm Bowel Dis 2021; 27:1766.</a></li><li><a class="nounderline abstract_t">Cold F, Kousgaard SJ, Halkjaer SI, et al. Fecal Microbiota Transplantation in the Treatment of Chronic Pouchitis: A Systematic Review. Microorganisms 2020; 8.</a></li><li><a class="nounderline abstract_t">Kousgaard SJ, Nielsen HL, Kirk KF, Thorlacius-Ussing O. Consumption of yoghurt favours remission after faecal microbiota transplantation for chronic pouchitis. Int J Colorectal Dis 2020; 35:1955.</a></li><li><a class="nounderline abstract_t">Wischmeyer P, Pemberton JH, Phillips SF. Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study. Mayo Clin Proc 1993; 68:978.</a></li><li><a class="nounderline abstract_t">Tremaine WJ, Sandborn WJ, Wolff BG, et al. Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 1997; 11:1041.</a></li><li><a class="nounderline abstract_t">Hahnloser D, Pemberton JH, Wolff BG, et al. Pregnancy and delivery before and after ileal pouch-anal anastomosis for inflammatory bowel disease: immediate and long-term consequences and outcomes. Dis Colon Rectum 2004; 47:1127.</a></li><li><a class="nounderline abstract_t">Seligman NS, Sbar W, Berghella V. Pouch function and gastrointestinal complications during pregnancy after ileal pouch-anal anastomosis. J Matern Fetal Neonatal Med 2011; 24:525.</a></li><li><a class="nounderline abstract_t">Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis 2017; 11:649.</a></li><li><a class="nounderline abstract_t">Nguyen GC, Seow CH, Maxwell C, et al. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology 2016; 150:734.</a></li><li><a class="nounderline abstract_t">Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68:s1.</a></li><li><a class="nounderline abstract_t">Navaneethan U, Shen B. Pros and cons of antibiotic therapy for pouchitis. Expert Rev Gastroenterol Hepatol 2009; 3:547.</a></li><li><a class="nounderline abstract_t">Quinn KP, Urquhart SA, Janssens LP, et al. Primary Sclerosing Cholangitis-Associated Pouchitis: A Distinct Clinical Phenotype. Clin Gastroenterol Hepatol 2022; 20:e964.</a></li><li><a class="nounderline abstract_t">Barnes EL, Holubar SD, Herfarth HH. Systematic Review and Meta-analysis of Outcomes After Ileal Pouch-anal Anastomosis in Primary Sclerosing Cholangitis and Ulcerative Colitis. J Crohns Colitis 2021; 15:1272.</a></li><li><a class="nounderline abstract_t">Navaneethan U, Venkatesh PG, Bennett AE, et al. Impact of budesonide on liver function tests and gut inflammation in patients with primary sclerosing cholangitis and ileal pouch anal anastomosis. J Crohns Colitis 2012; 6:536.</a></li><li><a class="nounderline abstract_t">Coletta M, Paroni M, Caprioli F. Successful Treatment With Vedolizumab in a Patient With Chronic Refractory Pouchitis and Primary Sclerosing Cholangitis. J Crohns Colitis 2017; 11:1507.</a></li><li><a class="nounderline abstract_t">Ardalan ZS, Sparrow MP. A Personalized Approach to Managing Patients With an Ileal Pouch-Anal Anastomosis. Front Med (Lausanne) 2019; 6:337.</a></li><li><a class="nounderline abstract_t">Shen B, Bennett AE, Navaneethan U. IgG4-associated pouchitis. Inflamm Bowel Dis 2011; 17:1247.</a></li><li><a class="nounderline abstract_t">Bilal M, Gulati A, Clarke K. Immunoglobulin G4 (IgG4)-associated pouchitis - Part of IgG4 related disease? A case series and review of the literature. Dig Liver Dis 2016; 48:817.</a></li><li><a class="nounderline abstract_t">Syal G, Shemtov R, Bonthala N, et al. Pre-pouch Ileitis is Associated with Development of Crohn's Disease-like Complications and Pouch Failure. J Crohns Colitis 2021; 15:960.</a></li><li><a class="nounderline abstract_t">Segal JP, Rottoli M, Felwick RK, et al. Biological therapy for the treatment of prepouch ileitis: a retrospective observational study from three centers. Clin Exp Gastroenterol 2018; 11:461.</a></li><li><a class="nounderline abstract_t">Bauer CM, Barnes EL, Herfarth HH. Tofacitinib in the Treatment of Crohn's-Like Disease of the Pouch. Am J Gastroenterol 2020; 115:2116.</a></li><li><a class="nounderline abstract_t">Shen B, Lashner BA, Bennett AE, et al. Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis. Am J Gastroenterol 2004; 99:1527.</a></li><li><a class="nounderline abstract_t">Shen B, Plesec TP, Remer E, et al. Asymmetric endoscopic inflammation of the ileal pouch: a sign of ischemic pouchitis? Inflamm Bowel Dis 2010; 16:836.</a></li><li><a class="nounderline abstract_t">Abbass MA, Lavryk OA, Hyman N, et al. Nonspecific, Acute Pouchitis in Patients With Familial Adenomatous Polyposis: Less Common Than We Think. Dis Colon Rectum 2022; 65:846.</a></li></ol></div><div id="topicVersionRevision">Topic 93857 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34416186" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31579976" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12794576" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11487535" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29995184" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Placebo Rates in Randomized Controlled Trials of Pouchitis Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23877758" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical value of surveillance pouchoscopy in asymptomatic ileal pouch patients with underlying inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30810748" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30295784" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22407820" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Adalimumab therapy in Crohn's disease of the ileal pouch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15645406" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Differentiating risk factors for acute and chronic pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31136680" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35447313" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The Effect of the Crohn's Disease Exclusion Diet on Patients With Pouch Inflammation: An Interventional Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30828722" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Fruit Consumption is Associated with Alterations in Microbial Composition and Lower Rates of Pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34774224" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11720319" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Early institution of tinidazole may prevent pouchitis following ileal pouch anal anastomosis (IPAA) surgery in ulcerative colitis (UC) patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8624195" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17279300" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19418603" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fecal coliform testing to identify effective antibiotic therapies for patients with antibiotic-resistant pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10383499" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15720360" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11966499" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34536075" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Long-term Antibiotic Treatment in Pouchitis-Patterns of Use and Safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31605691" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Predominantly Antibiotic-resistant Intestinal Microbiome Persists in Patients With Pouchitis Who Respond to Antibiotic Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32182609" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Increased Quinolone-Resistant Mutations of gyrA and parC Genes after Pouchitis Treatment with Ciprofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24075890" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Ileal pouch symptoms do not correlate with inflammation of the pouch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33735522" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2339922" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17368235" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17368235" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30360752" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The Epithelial Barrier Model Shows That the Properties of VSL#3 Depend from Where it is Manufactured.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10930365" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16197493" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14684584" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : VSL#3 for chronic pouchitis: experience in UK clinical practice</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18573211" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Rifaximin for maintenance therapy in antibiotic-dependent pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29588846" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Long-term follow-up of the use of maintenance antibiotic therapy for chronic antibiotic-dependent pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Topical administration of 5-aminosalicylic acid: a therapeutic proposal for the treatment of pouchitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23328773" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical course of cuffitis in ulcerative colitis patients with restorative proctocolectomy and ileal pouch-anal anastomoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19817724" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pilot study: the use of sulfasalazine for the treatment of acute pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28110377" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Sulfasalazine in Prevention of Pouchitis After Proctocolectomy with Ileal Pouch-Anal Anastomosis for Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11856075" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Budesonide enema in pouchitis--a double-blind, double-dummy, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31813214" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24394806" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Oral beclomethasone dipropionate in chronic refractory pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24394806" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Oral beclomethasone dipropionate in chronic refractory pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17451569" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Oral budesonide in the treatment of chronic refractory pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31187322" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31823641" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34245267" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34049383" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Safety and Efficacy of Biological Therapy in Chronic Antibiotic Refractory Pouchitis: A Systematic Review With Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36988594" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Vedolizumab for the Treatment of Chronic Pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31700634" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24579075" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long-term use of probiotics Lactobacillus and Bifidobacterium has a prophylactic effect on the occurrence and severity of pouchitis: a randomized prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34097166" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Is Ustekinumab Effective in Refractory Crohn's Disease of the Pouch and Chronic Pouchitis? A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21160308" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Infliximab and/or azathioprine in the treatment of Crohn's disease-like complications after IPAA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22395225" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19637335" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21826765" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30739519" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Adalimumab in the treatment of chronic pouchitis. A randomized double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32668342" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Recycling of Precolectomy Anti-Tumor Necrosis Factor Agents in Chronic Pouch Inflammation Is Associated With Treatment Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32130659" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A case of refractory chronic pouchitis successfully treated with tofacitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30734234" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Real-World Experience with Tofacitinib in IBD at a Tertiary Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28452863" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Efficacy and Factors Associated with Treatment Response of Intravenous Immunoglobulin in Inpatients with Refractory Inflammatory Bowel Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26319238" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hyperbaric oxygen therapy for chronic antibiotic-refractory ischemic pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32944766" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hyperbaric Oxygen Therapy in Chronic Inflammatory Conditions of the Pouch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32565291" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hyperbaric Oxygen Therapy Is Effective in the Treatment of Inflammatory and Fistulizing Pouch Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34003289" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The Effectiveness and Safety of Hyperbaric Oxygen Therapy in Various Phenotypes of Inflammatory Bowel Disease: Systematic Review With Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32596255" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Clostridioides Difficile Infection Is a Rare Cause of Infectious Pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Vancomycin in treatment of immune-mediated pouchitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Vancomycin in treatment of immune-mediated pouchitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34316379" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Oral vancomycin in the treatment of primary sclerosing cholangitis-associated pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35246974" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Vancomycin Is Effective in the Treatment of Chronic Inflammatory Conditions of the Pouch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26966529" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14984374" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14984374" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24022534" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Topical tacrolimus therapy for antibiotic-refractory pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30997086" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The efficacy of fecal microbiota transplantation for patients with chronic pouchitis: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32285709" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Clinical results and microbiota changes after faecal microbiota transplantation for chronic pouchitis: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31302808" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Fecal Microbiota Transplantation in Pouchitis: Clinical, Endoscopic, Histologic, and Microbiota Results from a Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26264409" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Variable alterations of the microbiota, without metabolic or immunological change, following faecal microbiota transplantation in patients with chronic pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26525055" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Successful treatment of chronic Pouchitis utilizing fecal microbiota transplantation (FMT): a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31172007" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Combined Endoscopic and Oral Fecal Microbiota Transplantation in Patients with Antibiotic-Dependent Pouchitis: Low Clinical Efficacy due to Low Donor Microbial Engraftment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33501942" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Fecal Microbiota Transplantation in Chronic Pouchitis: A Randomized, Parallel, Double-Blinded Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32962069" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Fecal Microbiota Transplantation in the Treatment of Chronic Pouchitis: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32504332" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Consumption of yoghurt favours remission after faecal microbiota transplantation for chronic pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8412364" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9663827" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15164253" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Pregnancy and delivery before and after ileal pouch-anal anastomosis for inflammatory bowel disease: immediate and long-term consequences and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20608799" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pouch function and gastrointestinal complications during pregnancy after ileal pouch-anal anastomosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28158501" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26688268" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31562236" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19817675" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Pros and cons of antibiotic therapy for pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33549866" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Primary Sclerosing Cholangitis-Associated Pouchitis: A Distinct Clinical Phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33544128" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Systematic Review and Meta-analysis of Outcomes After Ileal Pouch-anal Anastomosis in Primary Sclerosing Cholangitis and Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22398056" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Impact of budesonide on liver function tests and gut inflammation in patients with primary sclerosing cholangitis and ileal pouch anal anastomosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29106505" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Successful Treatment With Vedolizumab in a Patient With Chronic Refractory Pouchitis and Primary Sclerosing Cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32064264" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : A Personalized Approach to Managing Patients With an Ileal Pouch-Anal Anastomosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20722051" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : IgG4-associated pouchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27038705" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Immunoglobulin G4 (IgG4)-associated pouchitis - Part of IgG4 related disease? A case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33300546" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pre-pouch Ileitis is Associated with Development of Crohn's Disease-like Complications and Pouch Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30588057" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Biological therapy for the treatment of prepouch ileitis: a retrospective observational study from three centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32740085" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Tofacitinib in the Treatment of Crohn's-Like Disease of the Pouch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15307872" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19998461" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Asymmetric endoscopic inflammation of the ileal pouch: a sign of ischemic pouchitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34343160" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Nonspecific, Acute Pouchitis in Patients With Familial Adenomatous Polyposis: Less Common Than We Think.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
